PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
49.92
-2.15 (-4.13%)
Dec 3, 2024, 1:43 PM EST - Market open
PTC Therapeutics Employees
As of December 31, 2023, PTC Therapeutics had 1,055 total employees, including 988 full-time and 67 part-time employees. The number of employees decreased by 355 or -25.18% compared to the previous year.
Employees
1,055
Change (1Y)
-355
Growth (1Y)
-25.18%
Revenue / Employee
$853,710
Profits / Employee
-$429,574
Market Cap
3.85B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Acadia Healthcare Company | 23,500 |
DENTSPLY SIRONA | 15,000 |
ICU Medical | 14,000 |
Organon & Co. | 10,000 |
Perrigo Company | 9,140 |
Option Care Health | 7,802 |
Guardant Health | 1,779 |
Ultragenyx Pharmaceutical | 1,276 |
PTCT News
- 23 hours ago - PTC Therapeutics Stock Soars on Novartis Licensing Agreement - Investopedia
- 1 day ago - PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program - Benzinga
- 1 day ago - PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis - Reuters
- 1 day ago - PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program - PRNewsWire
- 6 days ago - PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs - Benzinga
- 6 days ago - PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million - PRNewsWire
- 6 days ago - PTC Therapeutics discontinues development of ALS drug after trial failure - Reuters
- 6 days ago - PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients - PRNewsWire